News

A 20 mg weekly oral dose of methotrexate shows potential as a low-cost treatment for reducing pain and stiffness in patients with symptomatic hand osteoarthritis, according to the results of the METHODS trial.

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.

This endocrine case report from Brady Pregerson, MD, features a man in his 50s with bilateral ankle and foot pain/swelling. Can you determine the correct diagnosis?

While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.

Hematologic malignancy was not affected by the type of biologics prescribed, treatment patterns, comedications, comorbidities, or cumulative defined daily doses.

In patients initiating allopurinal, adverse events were more common in those receiving concomitant colchicine or nonsteroidal anti-inflammatory drugs compared to those without prophylaxis.

The Patient Self-Report Survey for the Assessment of Fibromyalgia illustrated its accuracy in determining pain sensitivity and psychological factors in patients with shoulder or low back pain.

Patients with psoriatic disease have a significantly higher risk of developing a variety of autoimmune diseases, as indicated by the Charlson Comorbidity Index.

Self-injection of bimekizumab was generally well tolerated among patients with psoriatic arthritis.

This decision by the FDA could offer psoriatic arthritis patients a dosing regimen each month that does not require pre-mediation or regular lab assessments.

Retention rates for golimumab treatment at the 5-year mark were consistently high when used as a first-line therapy and did not significantly differ across conditions.

The overall cardiovascular burden was significantly higher in the fibromyalgia cohort when compared with the general Italian population.

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

Investigators found intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA in the FLORA trial cohort were associated with clinical response to FMT.

A systematic literature search reported an increase in both publications and cases of spinal gout.

Although the dietary intervention did not significantly reduce overall serum urate, it did decrease levels among those with baseline hyperuricemia.

Despite commonly understood symptoms and efficacious treatments, the stigmatizing nature of gout has caused significant setbacks to curbing its impact on Americans.

Patients with SARS-CoV-2 infection experienced a 22% increase in the incidence of immune-mediated inflammatory diseases, including T1DM, IBD, and psoriasis.

At the 6-month mark, a significant reduction was reported in both the widespread pain index and the symptom severity scale in patients with fibromyalgia undergoing a gluten-free diet.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.

Low allopurinol prescription rates and suboptimal dosing are of particular concern in adult patients in Asia with poorly controlled gout.

The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment.

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

Patients diagnosed with psoriatic arthritis and obesity were older, more frequently women, had worse pain, physical function, and health-related quality of life, and had higher tender joint and enthesitis counts when compared with nonobese patients.

A systematic review of 11 randomized clinical trials found adults with gout exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment.

Of the 130 patients with psoriatic arthritis who participated in a telemedicine assessment, 83% were happy with the consultation.

A recent study found initial monotherapy for chronic inflammatory arthritis yields better treatment persistence and safety relative to combination therapy.